COMMUNIQUÉS West-GlobeNewswire

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
30/09/2025
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
30/09/2025
Focal One ® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network AUSTIN, Texas [...]
Lung Health Foundation: 'Canadian Charities Face Obstacles as the Postal Strike Threatens to Block Millions in Essential Year-End Donations'
30/09/2025
Canada’s Largest Charity Dedicated to Lung Health Responds to the Launch of a Canada Post Strike TORONTO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- A postal strike in Canada disproportionately threatens the lifeblood of [...]
Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway
30/09/2025
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies for hard-to-heal wounds, today announced that it is scheduled [...]
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
30/09/2025
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how [...]
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
30/09/2025
ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia. ODM-105 (tasipimidine) was [...]
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
30/09/2025
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
30/09/2025
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo [...]
Dogecoin Cash Inc. (OTCQB:DOGP) Announces Special Distribution of DogeCoin Cash (MEMECOIN:DOG) to Shareholders
30/09/2025
MESQUITE, NV, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — Dogecoin Cash Inc. (OTCQB:DOGP) today announced that its Board of Directors has approved a special distribution of DogeCoin Cash (MEMECOIN:DOG) to [...]
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
30/09/2025
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor [...]
MSInsight Joins PREDI-LYNCH Project to Advance Non-Invasive Cancer Detection in Lynch Syndrome — Aligning With Hereditary Cancer Awareness Week
30/09/2025
Press Release Paris, September 2025 – MSInsight, a French precision oncology start-up, is proud to announce its participation in PREDI-LYNCH * , a six-year Horizon Europe consortium led by Oslo University Hospital. This [...]
MSInsight se joint au projet PREDI-LYNCH, une initiative européenne pour permettre d’identifier plus tôt les porteurs du syndrome de Lynch, l’une des principales prédispositions héréditaires au cancer.
30/09/2025
Communiqué de presse Paris, 29 septembre 2025 – MSInsight, start-up française de médecine de précision en oncologie, annonce sa participation au projet européen PREDI-LYNCH, un consortium coordonné par l’Hôpital [...]
Pulselight appoints Sir Jonathan Van-Tam as an Advisor
30/09/2025
Sir Jonathan Van-Tam joins Pulselight to support its mission to transform the UK health system by reducing waiting lists, driving efficiencies and improving patient outcomes LONDON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
30/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 30 September 2025 at 9.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
30/09/2025
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies. The test helps clinicians quickly identify heart attack and rule out non-cardiac [...]
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
30/09/2025
Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya [...]
Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ®
30/09/2025
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie [...]
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
30/09/2025
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced [...]
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
30/09/2025
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative [...]

Pages